Morgan Stanley’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.39M Sell
466,456
-105,578
-18% -$946K ﹤0.01% 4322
2026
Q1
$4.66M Sell
572,034
-3,145,950
-85% -$28.5M ﹤0.01% 4188
2025
Q4
$25M Buy
3,717,984
+2,641,540
+245% +$19.9M ﹤0.01% 2723
2025
Q3
$9.33M Sell
1,076,444
-162,342
-13% -$1.26M ﹤0.01% 3608
2025
Q2
$7.8M Sell
1,238,786
-739,154
-37% -$4.89M ﹤0.01% 3681
2025
Q1
$12.7M Sell
1,977,940
-2,962,175
-60% -$24.5M ﹤0.01% 3125
2024
Q4
$39.7M Buy
4,940,115
+3,387,896
+218% +$32.7M ﹤0.01% 2051
2024
Q3
$19.6M Sell
1,552,219
-150,516
-9% -$1.94M ﹤0.01% 2827
2024
Q2
$21.6M Sell
1,702,735
-167,595
-9% -$1.69M ﹤0.01% 2579
2024
Q1
$8.94M Sell
1,870,330
-5,371,125
-74% -$24.9M ﹤0.01% 3435
2023
Q4
$34.8M Buy
7,241,455
+4,966,324
+218% +$30.4M ﹤0.01% 2097
2023
Q3
$16.5M Buy
2,275,131
+194,694
+9% +$1.56M ﹤0.01% 2659
2023
Q2
$15.5M Sell
2,080,437
-373,402
-15% -$2.94M ﹤0.01% 2738
2023
Q1
$17M Buy
2,453,839
+674,445
+38% +$6.21M ﹤0.01% 2596
2022
Q4
$18.3M Buy
1,779,394
+685,214
+63% +$12.1M ﹤0.01% 2433
2022
Q3
$19.9M Sell
1,094,180
-192,009
-15% -$8.32M ﹤0.01% 2199
2022
Q2
$66.1M Buy
1,286,189
+383,415
+42% +$19.9M 0.01% 1192
2022
Q1
$66.5M Sell
902,774
-53,718
-6% -$4.79M 0.01% 1108
2021
Q4
$137M Buy
956,492
+270,868
+40% +$46.5M 0.02% 711
2021
Q3
$142M Buy
685,624
+215,448
+46% +$47.5M 0.02% 656
2021
Q2
$99.8M Buy
470,176
+183,024
+64% +$33.5M 0.01% 844
2021
Q1
$52.1M Sell
287,152
-61,431
-18% -$12.2M 0.01% 1147
2020
Q4
$38.9M Sell
348,583
-115,415
-25% -$12.3M 0.01% 1284
2020
Q3
$50.3M Buy
463,998
+215,103
+86% +$26.2M 0.01% 896
2020
Q2
$20.7M Sell
248,895
-187,576
-43% -$7.17M ﹤0.01% 1372
2020
Q1
$5.93M Buy
436,471
+307,875
+239% +$2.61M ﹤0.01% 2288
2019
Q4
$511K Sell
128,596
-365,083
-74% -$1.58M ﹤0.01% 4913
2019
Q3
$2.48M Sell
493,679
-160,288
-25% -$877K ﹤0.01% 3588
2019
Q2
$3.83M Buy
653,967
+388,987
+147% +$3.06M ﹤0.01% 3203
2019
Q1
$2.92M Buy
264,980
+64,036
+32% +$2.02M ﹤0.01% 3249
2018
Q4
$7.39M Buy
200,944
+26,923
+15% +$1.04M ﹤0.01% 2453
2018
Q3
$6.54M Sell
174,021
-139,613
-45% -$3.93M ﹤0.01% 2893
2018
Q2
$8.41M Buy
313,634
+179,833
+134% +$6.08M ﹤0.01% 2560
2018
Q1
$5.62M Sell
133,801
-10,743
-7% -$432K ﹤0.01% 2902
2017
Q4
$3.58M Sell
144,544
-9,003
-6% -$220K ﹤0.01% 3464
2017
Q3
$3.5M Buy
153,547
+799
+0.5% +$17.9K ﹤0.01% 3336
2017
Q2
$3.51M Sell
152,748
-4,601
-3% -$90.3K ﹤0.01% 3259
2017
Q1
$4.03M Sell
157,349
-10,647
-6% -$293K ﹤0.01% 3090
2016
Q4
$4.23M Buy
167,996
+21,723
+15% +$634K ﹤0.01% 3171
2016
Q3
$6.09M Buy
146,273
+8,495
+6% +$1.1M ﹤0.01% 2485
2016
Q2
$20M Sell
137,778
-31,875
-19% -$3.65M 0.01% 1426
2016
Q1
$17.5M Buy
169,653
+112,735
+198% +$12.1M 0.01% 1403
2015
Q4
$9.55M Sell
56,918
-8,249
-13% -$1.27M ﹤0.01% 2026
2015
Q3
$9.21M Sell
65,167
-6,919
-10% -$1.55M ﹤0.01% 2028
2015
Q2
$16.1M Sell
72,086
-5,941
-8% -$1.04M 0.01% 1689
2015
Q1
$12.9M Buy
78,027
+8,993
+13% +$1.46M ﹤0.01% 1809
2014
Q4
$8.19M Sell
69,034
-1,045
-1% -$109K ﹤0.01% 2255
2014
Q3
$5.84M Buy
70,079
+2,081
+3% +$188K ﹤0.01% 2509
2014
Q2
$6.28M Buy
67,998
+43,734
+180% +$3.84M ﹤0.01% 2462
2014
Q1
$2.2M Buy
24,264
+5,771
+31% +$645K ﹤0.01% 3337
2013
Q4
$1.89M Sell
18,493
-22,807
-55% -$1.61M ﹤0.01% 3412
2013
Q3
$2.6M Buy
41,300
+34,341
+493% +$1.93M ﹤0.01% 3011
2013
Q2
$285K Buy
+6,959
New +$302K ﹤0.01% 4629

Other funds holding NVAX

Morgan Stanley's NVAX Position: Q2 2026 in Review

Morgan Stanley reduced its Novavax (NVAX) stake by 18% in Q2 2026, selling an estimated $946K and leaving 466,456 shares worth $4.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

Morgan Stanley first reported a position in NVAX in Q2 2013 and has held it in 53 quarters since. The position peaked at $142M in Q3 2021. 265 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Morgan Stanley held 466,456 shares of Novavax worth $4.39M as of Q2 2026.
  • Morgan Stanley sold 105,578 Novavax shares in Q2 2026, an estimated $946K.
  • Novavax made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4322 holding.
  • Morgan Stanley first reported a position in Novavax in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's Novavax position peaked at $142M in Q3 2021.
  • 265 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.